Objectives. Autoantibody testing is helpful for predicting the risk of progression to clinical arthritis in subjects at risk. Previous longitudinal studies have mainly selected autoantibody-positive arthralgia patients, and consequently the predictive values of autoantibodies were evaluated relative to one another. This study assessed the risks for arthritis development of ACPA, RF and/or anti-carbamylated protein antibodies (anti-CarP) in arthralgia patients considered at risk for RA by rheumatologists, based on clinical characteristics (clinically suspect arthralgia, CSA).
Introduction
ACPA, RF and antibodies against carbamylated proteins (anti-CarP) can be present years before the first onset of symptoms of RA [13] . The initial observations on the association between autoantibodies and progression to clinical arthritis were largely done in nested casecontrol studies [2, 3] . The results of these studies cannot be directly used for risk assessment in clinical practice; longitudinal studies performed in daily rheumatologic practice are needed to this end [46] .
Most published longitudinal studies in arthralgia determined the predictive value of ACPA and RF in persons who were selected for the presence of these autoantibodies [4, 5, 7, 8] . Consequently, as a reference group of arthralgia patients without autoantibodies was not available, predictive values of the different autoantibodies were evaluated relative to one another [4, 5] . RF-positive patients were often used as the reference group, as presence of RF yielded the lowest risk of progression to clinical arthritis [5] . In addition, some of the patients in these studies had musculoskeletal symptoms, but were not referred to secondary care by general practitioners because of these symptoms [7] . The selection method and reference group used in these studies may affect generalizability of these findings for arthralgia patients presenting to rheumatology outpatients clinics. Therefore, the risks provided by different autoantibodies and by combinations of autoantibodies in patients presenting with arthralgia at risk for RA is still undetermined.
The present study evaluated patients with clinically suspect arthralgia (CSA); these are patients without clinical arthritis who are considered to be at risk of progression to RA by their rheumatologists, based on the clinical presentation. Identification of patients at risk based on clinical expertise is to some extent subjective; to allow inclusion of a more homogeneous group of patients in studies, a EULAR definition for arthralgia suspicious for progression to RA was recently developed [9] . This definition is intended for use in arthralgia patients without clinical arthritis and in whom imminent RA is considered more likely than other explanations. This will generate a more homogeneous set of arthralgia patients at risk for RA and may facilitate generalizability of findings to arthralgia patients in other outpatient clinic settings.
To determine the value of RA-related autoantibodies in patients with CSA, this study aimed to: determine progression to clinical arthritis and the absolute risks provided by ACPA, RF and anti-CarP antibodies. Determine the risk provided by combinations of the commercially available autoantibody tests: ACPA and RF. Evaluate whether higher ACPA and RF levels conferred higher rates of progression to clinical arthritis. In addition, subanalyses were performed in which we aimed to investigate differences in the baseline characteristics of ACPA-positive/RF-positive patients who did or did not progress to clinical arthritis, and assess ACPA and RF levels over time, both in patients who progressed from CSA to arthritis and in patients who did not progress.
Methods

Patients
A total of 241 patients were consecutively included in the Leiden CSA cohort between April 2012 and March 2015, an inception cohort at the rheumatology outpatient clinic of the Leiden University Medical Centre, the Netherlands. Per definition, CSA patients had no clinical arthritis, but had recentonset (<1 year) arthralgia of hand or feet joints, and they were considered at risk for RA, based on the clinical expertise of the rheumatologists, as described previously [10] . Hence, patients were indicated as having CSA, based on the first clinical presentation. As general practitioners in the region are discouraged from performing autoantibody testing before referral [11, 12] , information on ACPA and RF status were generally unknown at secondary care presentation. After inclusion, questionnaires were filled out by patients and rheumatologists, joint counts performed, blood samples taken and a unilateral contrast-enhanced MRI was made of the secondfifth MCP, wrist and firstfifth MTP joints of the most painful side (or the dominant side in the case of equally severe symptoms on both sides) using an MSK Extremity 1.5 T MRI scanner, as described elsewhere [10, 11] and in the supplementary Methods, available at Rheumatology Online. Regular follow-up visits were scheduled at 4, 12 and 24 months, and additional visits occurred in between if indicated (either if felt necessary by rheumatologists or at the request of patients because of an increase in symptom severity). Treatment with DMARDs was not allowed during the CSA study; NSAIDs were allowed. The CSA cohort has been approved by the local medical ethical committee (named 'Commissie Medische Ethiek'). All participants provided written informed consent according to the Declaration of Helsinki.
Autoantibody determination
At the baseline visit, IgG ACPA [EliA CCP (anti-CCP2), Phadia, Nieuwegein, the Netherlands], IgM RF (as described previously, in-house ELISA [13] ) and IgG antiCarP antibodies were determined. The cut-off for ACPA positivity was >7 U/ml, and for RF positivity it was >3.5 IU/ml, according to the manufacturer's instructions. Anti-CarP was determined as described previously [14] . As no commercial kit is available for anti-CarP antibodies, we used our in-housedeveloped anti-CarP assay based on carbamylated fetal calf serum, and as a control the non-modified fetal calf serum as the coating antigens in ELISA [14] . The cut-off was equivalent to 2 S.D. above the mean in a group of healthy controls. The healthy controls consisted of a group of 197 healthy blood donors between 20 and 70 years old. The mean (S.D.) age of the controls was 44.4 years (range 2070 years, S.D. 14). Of the controls, 50.8% were female. Controls were not allowed to have a rheumatic disease. Of those same controls, 65.5% had never smoked, 26.9% had previously smoked and 6.6% were current smokers; for two controls, data on smoking status was missing. ACPA and RF status were repeated after 2 years, or at the time of conversion to clinical arthritis. Outcome All patients were followed for 556 weeks. The median follow-up duration was 103 weeks [interquartile range (IQR) 81114 weeksz0. None of the patients were treated with DMARDs or CSs in the phase of CSA. The primary end point was development of arthritis detected at physical examination (66 joints assessed) by the rheumatologist. Medical records of all patients were studied for established clinical arthritis until 22 April 2016. Persistent arthritis was studied as the secondary end point, which was defined as (through study of the medical record) clinical arthritis that persisted at two subsequent visits, or when DMARDs were prescribed when clinical arthritis was identified. The 2010 classification criteria for RA [15] were considered less suitable as a secondary outcome, as autoantibody-negative patients require >10 involved joints to fulfil these criteria [16] . DMARDs were generally started shortly after patients had developed clinically evident arthritis, and this may have prevented progression from unclassified arthritis to RA, particularly for autoantibody-negative patients.
Statistical analyses
Univariable and multivariable Cox proportional hazards regression analyses were performed with clinical arthritis as the outcome. Time to clinical arthritis was defined as time from inclusion date in the cohort to the date of first detection of clinical arthritis. Patients who did not develop arthritis were censored at either the date when all medical files were studied on arthritis development or at the date of the 24-month follow-up visit. When evaluating the hazard ratios (HRs) and absolute risks for combinations of autoantibodies, we mainly restricted ourselves to the two commercially available autoantibodies (ACPA and RF), because otherwise small subgroups would be obtained (supplementary Fig. S1 , available at Rheumatology Online). To determine the association for arthritis development with autoantibody level, patients were categorized into tertiles based on the ACPA levels of ACPA-positive patients in our cohort, or RF levels in RF-positive patients in our cohort (hence creating three groups of similar size). For ACPA, these categories were 795 U/ml (with n = 10), 96325 U/ml (n = 11) and 5326 U/ml (n = 11). For RF, the categories were 3.510 IU/ml (with n = 17), 1140 IU/ml (n = 17) and 541 IU/ml (n = 17). Test characteristics and predictive values with 95% CIs were calculated. Patient characteristics were compared using MannWhitney U tests, t-tests and Chi-square tests, as appropriate.
In addition to the analyses on all CSA patients, the most important analyses were repeated in the subgroup of patients who also fulfilled the EULARdefinition of arthralgia suspicious for progression to RA (3/7 items present) [9] . Statistical analyses were carried out using the Statistical Package for the Social Sciences (SPSS, version 23.0). P < 0.05 was considered significant.
Results
Patients with CSA
Baseline characteristics of the 241 CSA patients are shown in Table 1 . During a median follow-up period of 103 (IQR: 81114) weeks, 44 patients progressed to clinical arthritis (Fig. 1) . The secondary end point was obtained in 41 patients (3 patients had clinical arthritis on only one occasion that resolved spontaneously (without DMARD treatment) before the next visit; one patient had clinical arthritis in a wrist joint and two patients in the elbow joint).
Presence of autoantibodies and HR for progression to clinical arthritis
In univariable Cox regression, presence of ACPA was associated with arthritis development (HR 8.5; 95% CI: 4.715.4). A similar observation was made for presence of RF (HR = 5.1; 95% CI: 2.89.3) and for anti-CarP antibodies (HR = 3.9; 95% CI: 1.97.7). Multivariable analysis including all three autoantibodies-to correct for the simultaneous presence of the autoantibodies-revealed an independent significant association for ACPA only (HR = 5.1; 95% CI: 2.013.2); the HRs for RF and anti-CarP antibodies were 2.0 (95% CI: 0.814.9) and 1.04 (95% CI: 0.462.4), respectively. When age, gender, smoking and positive family history for RA were also included in the multivariable model, only ACPA was significantly associated with progression to RA (HR = 5.3; 95% CI: 2.014.2). suspicious for progression to RA [9] , n (%)
178 (74) Autoantibody status IgM-RF-positive, >3.5 IU/ml, n (%) 51 (21) ACPA-positive, >7 U/ml, n (%) 32 (13) Anti-CarP positive, >2 S.D., n (%)
23 (10) IgM-RF: immunoglobulin M RF; IQR: interquartile range; TJC: tender joint count.
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Combinations of ACPA and RF and associated hazards
Combinations of ACPA and RF were studied next, as these are the commercially available tests and are most commonly used in daily rheumatologic care. With autoantibody-negative CSA patients as a reference, ACPAnegative/RF-positive patients had a HR of 2.6 (95% CI: 1.046.6) for developing clinical arthritis. ACPA-positive/ RF-negative had a HR of 8.0 (95% CI: 2.427.4), and ACPA-positive/RF-positive patients had a HR of 10.5 (95% CI: 5.420.6) (see Fig. 2 .) The hazard was not significantly different between the ACPA-positive/RFnegative and the ACPA-positive/RF-positive patients (P = 0.78), but there was a significantly different HR between the ACPA-negative/RF-positive and the ACPApositive/RF-positive patients (P = 0.005). Although subgroups became small when anti-CarP was also considered (supplementary Fig. S1 , available at Rheumatology Online), there were no significant associations of anti-CarP with arthritis development within ACPA-negative/RF-negative or within ACPA-positive/RFpositive patients (HR = 2.7; 95% CI: 0.6211.9 and HR = 1.0; 95% CI: 0.372.7, respectively).
Association of autoantibody levels and arthritis development
In RA, presence of multiple autoantibodies is associated with higher autoantibody levels [17, 18] . In CSA patients, higher ACPA levels were observed in ACPA-positive/RFpositive patients than in ACPA-positive/RF-negative patients (median 237.5 vs 94 U/ml, P = 0.17). Within the ACPA-positive patients, ACPA levels were not associated with higher hazards for progression to clinical arthritis (Fig. 3A) . RF levels were significantly higher in ACPA-positive/RF-positive patients compared with ACPA-negative/ RF-positive patients (median 36 vs 12.5 IU/ml, respectively, P = 0.007). In addition, patients with RF levels 541 IU/ml (highest tertile) had significantly increased hazard to progress to clinical arthritis (HR = 3.3; 95% CI: 1.19.6) compared with patients with RF levels 3.5, 10 IU/ ml (lowest tertile, Fig. 3B ).
Absolute risks and test characteristics for arthritis development at 2-year follow-up
In order to arrive at absolute risks for developing clinical arthritis of the individual autoantibodies and combinations of ACPA and RF, patients who completed a 2-year follow- up were studied (n = 144). The positive predictive values (PPVs) for arthritis development within 2 years were: 63% for ACPA, 53% for RF and 50% for anti-CarP antibodies. Considering combinations of ACPA and RF, the PPV for ACPA-negative/RF-positive patients was 38%. For ACPApositive/RF-negative patients, the PPV was 50% and for ACPA-positive/RF-positive patients 67% (Table 2) . Thus, of the ACPA-positive/RF-positive patients, 33% did not develop arthritis within 2 years. Sub-analyses with the secondary end point (persistent clinical arthritis) showed similar results (supplementary Table S1 , available at Rheumatology Online). Table S2 , available at Rheumatology Online. Of the ACPA-positive/RF-positive patients who fulfilled the EULAR definition, 31% did not progress to RA.
Baseline characteristics of ACPA-positive/RF-positive CSA patients who progressed to arthritis vs those who did not
We hypothesized that patients progressing to clinical arthritis had either higher autoantibody levels or more extended (systemic or local subclinical) inflammation than patients who did not progress. Therefore, we then explored whether ACPA-positive/RF-positive CSA patients who did not progress to arthritis during the 2-year follow-up differed in baseline characteristics from those who progressed. Although the number of patients in both groups was small, no statistically significant or clinically relevant differences were observed (Table 3) .
Serum levels of ACPA and RF over time The autoantibody status and autoantibody levels were also assessed in patients who had completed a 2-year follow-up and did not progress to clinical arthritis (n = 114). Of these patients, 10 were ACPA-positive at inclusion, and none of these patients changed in ACPA status during follow-up. The median ACPA level in these non-converting patients was 304 U/ml at baseline and 340 U/ml after 2 years. Similarly, 16 patients not progressing to clinical arthritis were RF-positive at baseline; during follow-up, one RF-positive patient became RF-negative (levels 4.3 and 3.0 IU/ml, respectively) and one RF-negative patient became RF-positive after 2 years (levels <0.4 and 12.0 IU/ml, respectively). The median RF level in the non-converting patients was 16.5 IU/ml at baseline and 11 IU/ml after 2 years. Thus, overall the status and levels of ACPA and RF were rather stable during the 2-year follow-up, both in patients who progressed to clinical arthritis and in patients who did not progress to clinical arthritis.
Discussion
Early recognition of patients with imminent RA is an important but challenging topic. Autoantibodies have proven to be the most powerful predictors for development of clinical arthritis currently available. This study thoroughly determined the risks of individual autoantibodies, combinations of autoantibodies, and autoantibody levels in patients who were considered to be at risk for RA, based on their clinical presentation. The absolute risks for progression to arthritis may be useful for daily clinical practice in places where patients present with arthralgia to rheumatology outpatient clinics. We observed that ACPA, RF and anti-CarP antibodies were associated with increased risks, but that only ACPA was independently associated with development of RA in multivariable analysis. Furthermore, although ACPA was clearly additive to RF in predicting risks, vice versa, RF was less additive to ACPA. A previous study by Van Steenbergen et al. [11] evaluated the risk indicated by ACPA, but not by the other autoantibodies in CSA. The current study explored the different characteristics of several different autoantibodies in CSA, in a larger study population and during a longer duration of follow-up. As previously described, the absolute risk of ACPA for arthritis development within 2 years was 63%. Previous studies in other at-risk populations found lower PPVs. A study in ACPA-positive patients with non-specific musculoskeletal complaints showed a progression to clinical arthritis rate of 47% within 12 months [7] . A study in ACPA-positive and/or RF-positive arthralgia patients found a PPV of 35% during the first year [8] . PPVs are dependent on the enrichment (i.e. prevalence) of cases in cohort studies, meaning that the same test may yield different results depending on the setting. Patients who are identified as having CSA by rheumatologists comprise a small group of all patients presenting with arthralgia to secondary care (<6%) [19] . This yielded higher prior chances for RA development in CSA patients than in patients with non-specific arthralgia in secondary or in primary care. Presumably, this explains the higher post-test chances of ACPA in this setting.
CSA is defined by the clinical expertise of rheumatologists and is therefore subjective. A EULAR taskforce has recently derived a definition of arthralgia suspicious for progression to RA, in order to strip CSA from its subjectivity and to allow the evaluation of a more homogeneous group of patients. Although further longitudinal studies on the accuracy of the EULAR definition are required, the present data suggest that the clinical expertise of the rheumatologists was often in line with the EULAR definition.
In the present data, despite small numbers, higher RF levels were associated with an increased risk of progression to clinical arthritis. Furthermore, patients with higher RF levels were also more often ACPA positive. RF-positive/ACPA-positive patients had a higher risk of developing clinical arthritis than RF-positive/ACPA-negative patients. Hence, these findings are compatible with one another. ACPA levels were not associated with a significantly increased risk of developing arthritis. This finding is in line with that of non-significant differences in the risk of developing arthritis between ACPA-positive/RF-positive and ACPA-positive/RF-negative patients, as both groups also had no significant differences in ACPA level. However, it should be noted that the subgroups of patients with the various autoantibody levels were small. This is the first longitudinal study evaluating the effect of anti-CarP antibodies in relation to RF and ACPA in CSA. A previous study observed an association of anti-CarP antibodies with arthritis development in non-specific autoantibody-positive arthralgia, but did not perform multivariable analysis including all three autoantibodies with an autoantibody-negative group as reference [6] . In our study, anti-CarP antibodies were not independently associated with arthritis development, and a significant effect of anti-CarP, additive to ACPA and RF, could not be shown. However, the current anti-CarP antibody test is not commercially available, which would allow further optimization and afterwards evaluation in larger studies.
ACPA and RF levels were rather stable over time, both in CSA patients who developed clinical arthritis and in patients who did not progress. Seroconversion during the study was rarely observed for RF and absent for ACPA. The finding of stable ACPA levels in the phase of CSA and during progression to clinical (persistent) arthritis suggests that the broadening of the autoantibody response may already have occurred in an earlier, and perhaps asymptomatic, pre-arthritis phase. This study had limitations. A large limitation is the sample size of the subgroup analyses; in particular, the ACPA-positive/RF-negative subgroup was small. Validation of the presented findings in other cohorts of arthralgia suspicious for progression to RA is needed. The primary outcome used was clinically apparent arthritis. As arthritis can be subtle in very early stages, and as variation between rheumatologists exists in sensitivity for detecting clinical arthritis, sub-analyses were performed with clinical arthritis that was persistent at two subsequent visits, or that was treated with DMARDs, as the outcome (both reflect chronic disease). These analyses provided similar results.
Based on the results of casecontrol studies revealing that the simultaneous presence of ACPA and RF almost never occurs in healthy controls [20, 21] , it is sometimes suggested that the presence of both ACPA and RF in arthralgia is a guarantee for progression to clinical arthritis and RA. However, this was not observed in the present study and our findings are in line with the results of other longitudinal studies. Bos et al. [5] showed that 60% of ACPApositive/RF-positive patients with non-specific arthralgia did not progress to clinical arthritis. Another study showed that 42% of ACPA-positive/anti-CarP-positive patients did not progress to arthritis [6] . Thus, previous studies have also shown that the presence of several autoantibodies in arthralgia was not always associated with arthritis development.
We hypothesized that ACPA-positive/RF-positive patients who did or did not progress would have lower autoantibody levels or less severe subclinical inflammation. However, no apparent differences were observed. An explanation for patients not progressing to clinical arthritis might be that the remaining ACPA-positive/RF-positive CSA patients will progress to clinical arthritis later on. Although we cannot exclude this, the KaplanMeier curves indicated that ACPA-positive/RF-positive patients mostly progressed in the first year and few converted in the second year. This makes the hypothesis that many subjects will progress after additional follow-up less likely. Other explanations are that patients who are truly pre-RA have differences in the molecular characteristics of the autoantibodies themselves, or that another trigger (on top of the presence of autoantibodies) is required for developing clinically evident arthritis. This is a subject of further research.
In summary, the presence of autoantibodies in CSA conferred increased absolute risks of developing clinical arthritis. Furthermore, PPVs in CSA were higher than those reported in non-specific arthralgia. However, also within CSA, the presence of ACPA alone or a combination of ACPA and RF is insufficient for identifying patients with imminent ACPA-positive RA with high accuracy (e.g. with PPVs >80%). Thus, in addition to clinical characteristics and autoantibodies, other biomarkers are needed for optimal prognostication.
